European Medicines Agency Issues Negative Opinion on Omeros Corporation Drug
What happened
The European Medicines Agency adopted a negative opinion on Omeros Corporation's marketing authorization application for narsoplimab for TA-TMA. This decision followed an oral explanation meeting with the Committee for Medicinal Products for Human Use. Separately, Pomerantz LLP confirmed it is investigating claims on behalf of investors regarding potential securities fraud or unlawful business practices by Omeros Corporation and its officers.
From prnewswire.com
Why it matters
The negative opinion from the European Medicines Agency affects Omeros Corporation's regulatory standing in Europe. The ongoing investor investigation by Pomerantz LLP could impact Omeros Corporation's market price and business operations.
From prnewswire.com
Who's involved
- Omeros CorporationCompany whose drug application received a negative opinion from the European Medicines Agency.
- European Medicines AgencyRegulatory body that adopted a negative opinion on Omeros Corporation's marketing authorization application.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Omeros CorporationSpeculative
Omeros Corporation might see its market price affected due to the negative opinion from the European Medicines Agency.
Keep exploring
The entities involved
-
Omeros Corporation
company in Seattle, United States
Nothing else this week.
-
European Medicines Agency
highest regulatory authority on medicines in the European Union